Campfieldtx
2 known investors
cAMPfield is a clinical-stage biopharmaceutical company developing prifemilast, a once-daily oral PDE4B-selective inhibitor for immune-mediated inflammatory diseases, primarily inflammatory bowel disease (ulcerative colitis and Crohn's disease). The company is advancing the drug into global Phase 2 clinical development.
Founders & leadership
GH
Graham HeapPresident, Research and Development
EN
Ezequiel NeimarkHead of Clinical Development
TS
Taylor SpectorHead of Medical Affairs
SS
Scott StirnHead of CMC